Trial Profile
Disposition of 14C-LY3009104 Following Oral Administration in Healthy Human Male Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Jun 2017
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacokinetics
- Sponsors Eli Lilly and Company
- 01 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
- 01 Apr 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.